News Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™ Continue Reading Previous Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B ProgramNext Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron Related Stories News TMX Group Thanksgiving Holiday Market Closures News TIPAK Marks Path to Leadership in Packaging Solutions Following Listing on SET News Chervon Names Daniel L. Abbott Director of Sales – Western U.S.A. News Chervon Names Peter J. Carlson Director of Sales for Strategic Accounts News Chervon Appoints Neil Harrison to the Position of VP Sales, Marketing and MD for Chervon Canada News Pelican Announces Appointment of Nino Di Teodoro to Its Board of Directors